WO2009078423A1 - アルドース還元酵素阻害活性を有する縮合三環化合物 - Google Patents

アルドース還元酵素阻害活性を有する縮合三環化合物 Download PDF

Info

Publication number
WO2009078423A1
WO2009078423A1 PCT/JP2008/072942 JP2008072942W WO2009078423A1 WO 2009078423 A1 WO2009078423 A1 WO 2009078423A1 JP 2008072942 W JP2008072942 W JP 2008072942W WO 2009078423 A1 WO2009078423 A1 WO 2009078423A1
Authority
WO
WIPO (PCT)
Prior art keywords
tricyclic compound
fused tricyclic
atom
inhibitory activity
group
Prior art date
Application number
PCT/JP2008/072942
Other languages
English (en)
French (fr)
Inventor
Naoki Toyooka
Atsushi Kato
Isao Adachi
Original Assignee
National University Corporation University Of Toyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation University Of Toyama filed Critical National University Corporation University Of Toyama
Priority to JP2009546274A priority Critical patent/JP5366211B2/ja
Priority to EP08863348A priority patent/EP2179999A4/en
Publication of WO2009078423A1 publication Critical patent/WO2009078423A1/ja
Priority to US12/704,051 priority patent/US8198447B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

【課題】アルドース還元酵素阻害活性を有する縮合三環化合物の提供を目的とする。 【解決手段】一般式　(Ｉ)　 「式中、Ｒ１は、水素原子、ハロゲン原子等を;Ｒ２は、保護されていてもよいカルボキシル基を;Ｒ３は、水素原子、ハロゲン 原子等を;Ａは、アルキレン基を;Ｂは、酸素原子、硫黄原子または式 (ＩＩ)　(式中、Ｒ4 は、アリール、シクロアルキルもしくは複素環式基で置換されたアルキル基またはアリール基を示す。)を;Ｘは、 酸素原子または硫黄原子を、それぞれ示す。」 で表される縮合三環化合物。
PCT/JP2008/072942 2007-12-18 2008-12-17 アルドース還元酵素阻害活性を有する縮合三環化合物 WO2009078423A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009546274A JP5366211B2 (ja) 2007-12-18 2008-12-17 アルドース還元酵素阻害活性を有する縮合三環化合物
EP08863348A EP2179999A4 (en) 2007-12-18 2008-12-17 CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT
US12/704,051 US8198447B2 (en) 2007-12-18 2010-02-11 Fused tricyclic compound having aldose reductase inhibitory activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-325944 2007-12-18
JP2007325944 2007-12-18
JP2008273685 2008-10-24
JP2008-273685 2008-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/704,051 Continuation US8198447B2 (en) 2007-12-18 2010-02-11 Fused tricyclic compound having aldose reductase inhibitory activity

Publications (1)

Publication Number Publication Date
WO2009078423A1 true WO2009078423A1 (ja) 2009-06-25

Family

ID=40795537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072942 WO2009078423A1 (ja) 2007-12-18 2008-12-17 アルドース還元酵素阻害活性を有する縮合三環化合物

Country Status (4)

Country Link
US (1) US8198447B2 (ja)
EP (1) EP2179999A4 (ja)
JP (1) JP5366211B2 (ja)
WO (1) WO2009078423A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011157332A (ja) * 2010-02-03 2011-08-18 Toyama Univ ＰＰＡＲγアゴニスト
WO2012157744A1 (ja) * 2011-05-19 2012-11-22 国立大学法人 富山大学 １－チオキソ－１,２,３,４－テトラヒドロ－β－カルボリン誘導体およびそれらを含有する抗がん剤
JP2013505946A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
EP2658851B1 (en) * 2010-12-28 2015-03-11 Cadila Healthcare Limited Heterocyclic compounds suitable for the treatment of dyslipidemia
US10730886B2 (en) * 2015-09-04 2020-08-04 Shin Poong Pharmaceutical Co., Ltd. Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115470A2 (fr) * 2004-04-30 2005-12-08 Centre National De La Recherche Scientifique COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2006011750A1 (en) 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
WO2006058088A2 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115470A2 (fr) * 2004-04-30 2005-12-08 Centre National De La Recherche Scientifique COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2006011750A1 (en) 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
WO2006058088A2 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCH. PHARM., vol. 320, 1987, pages 22 - 29
CHEM. PHARM. BULL., vol. 45, 1997, pages 1248 - 1253
DIABETES COMPLICATIONS, vol. 21, no. 1, 2007, pages 25 - 32

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9469641B2 (en) 2008-03-24 2016-10-18 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
JP2013505946A (ja) * 2009-09-23 2013-02-21 メディベイション テクノロジーズ， インコーポレイテッド ピリド［３，４−ｂ］インドールおよび使用方法
AU2010298167B2 (en) * 2009-09-23 2015-12-24 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
JP2011157332A (ja) * 2010-02-03 2011-08-18 Toyama Univ ＰＰＡＲγアゴニスト
WO2012157744A1 (ja) * 2011-05-19 2012-11-22 国立大学法人 富山大学 １－チオキソ－１,２,３,４－テトラヒドロ－β－カルボリン誘導体およびそれらを含有する抗がん剤
JPWO2012157744A1 (ja) * 2011-05-19 2014-07-31 国立大学法人富山大学 １−チオキソ−１，２，３，４−テトラヒドロ−β−カルボリン誘導体およびそれらを含有する抗がん剤

Also Published As

Publication number Publication date
EP2179999A1 (en) 2010-04-28
US20100145052A1 (en) 2010-06-10
JPWO2009078423A1 (ja) 2011-04-28
EP2179999A4 (en) 2011-06-08
US8198447B2 (en) 2012-06-12
JP5366211B2 (ja) 2013-12-11

Similar Documents

Publication Publication Date Title
WO2009078423A1 (ja) アルドース還元酵素阻害活性を有する縮合三環化合物
EP1889842A4 (en) HETEROCYCLIC CONNECTION
WO2005105096A3 (en) Fused heterocyclic compounds
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
WO2007030582A3 (en) Acyclic ikur inhibitors
EP1968131A4 (en) ORGANIC ELECTROLUMINESCENT DEVICE AND MATERIAL THEREFOR
WO2005072412A3 (en) Anti-viral therapeutics
TW200732306A (en) Pyrimidine derivatives
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008130021A3 (en) Heterocyclic hydrazide compound and pesticidal use of the same
WO2009051244A1 (ja) 複素環化合物
WO2007133352A3 (en) Macrocyclic kinase inhibitors
EP1726584A4 (en) 2-AMINOCHINAZOLINDERIVAT
WO2008057855A3 (en) Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
WO2006047772A3 (en) Tricyclic spacer systems for nonlinear optical devices
WO2008126889A1 (ja) ヒドラジド化合物及びそれを含有する有害節足動物防除剤
WO2009048101A1 (ja) アミド化合物
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
TW200745032A (en) Novel heterobicyclic derivatives
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
WO2008126890A1 (ja) ヒドラジド化合物およびそれを含有する有害節足動物防除剤
WO2009025358A1 (ja) 複素環化合物およびその用途
WO2009057784A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863348

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009546274

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008863348

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE